The current financial score of Prime Medicine Inc is 6.04. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.15M, representing a year-over-year increase of 3.50%, while its net profit experienced a year-over-year increase of 19.93%.
The current valuation score of Prime Medicine Inc is 6.11. Its current P/E ratio is -2.54, which is -71.86% below the recent high of -0.71 and -469.25% above the recent low of -14.45.
The current earnings forecast score of Prime Medicine Inc is 8.15. The average price target is 7.11, with a high of 11.00 and a low of 4.25.
The current price momentum score of Prime Medicine Inc is 4.13. Currently, the stock price is trading between the resistance level at 3.66 and the support level at 2.80, making it suitable for range-bound swing trading.
The current institutional shareholding score of Prime Medicine Inc is 5.00. The latest institutional shareholding proportion is 68.55%, representing a quarter-over-quarter increase of 9.13%. The largest institutional shareholder is Catherine Wood, holding a total of 8.35M shares, representing 0.20% of shares outstanding, with 61.78% increase in holdings.
The current risk assessment score of Prime Medicine Inc is 3.98. The company's beta value is 2.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.